{
    "title": "115_s2260",
    "content": "SECTION 1. SHORT TITLE.\n\n    This Act may be cited as the ``Opioids and STOP Pain Initiative \nAct''.\n\nSEC. 2. ESTABLISHMENT.\n\n    There is established an Opioids and STOP Pain Initiative, to be \nadministered by the Director of the National Institutes of Health, in \ncoordination with other agencies, as appropriate, which shall include \nefforts to support research on the following:\n            (1) Section 108 of the Comprehensive Addiction and Recovery \n        Act of 2016 (42 U.S.C. 284q-1), known as the STOP Pain Act, \n        which directs the National Institutes of Health to intensify \n        and coordinate fundamental, translational, and clinical \n        research with respect to--\n                    (A) the understanding of pain;\n                    (B) the discovery and development of therapies for \n                chronic pain; and\n                    (C) the development of alternatives to opioids for \n                effective pain treatments.\n            (2) Developing improved options and evidence for \n        medication-assisted treatment.\n            (3) Developing improved options and evidence for opioid \n        overdose reversal treatments.\n            (4) The Federal Pain Research Strategy, including research \n        that focuses on--\n                    (A) novel drugs, non-addictive, and non-\n                pharmacological treatments for pain;\n                    (B) screening tools and outcome measures for \n                assessments across the continuum of pain;\n                    (C) national registries, datasets, and research \n                networks;\n                    (D) effective models of care delivery for pain \n                management; and\n                    (E) precision medicine methodology to prevent and \n                treat pain.\n            (5) The components of the Department of Health and Human \n        Services five-point strategy to address the opioid crisis that \n        states: ``Providing support for cutting edge research on pain \n        and addiction''.\n            (6) The pain therapy screening program established under \n        section 4.\n            (7) Other elements that the Secretary of Health and Human \n        Services may designate, in consultation with the Director of \n        the National Institutes of Health.\n\nSEC. 3. FUNDING FOR THE OPIOIDS AND STOP PAIN INITIATIVE.\n\n    (a) In General.--There is authorized to be appropriated, and there \nis appropriated, $5,000,000,000, to be used during the 5-fiscal year \nperiod beginning in the fiscal year in which such funds are \nappropriated, to the National Institutes of Health Innovation Account \nto be used to administer the Opioids and STOP Pain Initiative \nestablished under section 2.\n    (b) Emergency Spending.--\n            (1) In general.--Amounts appropriated under subsection (a) \n        are designated as an emergency requirement pursuant to section \n        4(g) of the Statutory Pay-As-You-Go Act of 2010 (2 U.S.C. \n        933(g)).\n            (2) Designation in the senate.--In the Senate, amounts \n        appropriated under subsection (a) are designated as an \n        emergency requirement pursuant to section 403(a) of S. Con. \n        Res. 13 (111th Congress), the concurrent resolution on the \n        budget for fiscal year 2010.\n\nSEC. 4. PAIN THERAPY SCREENING PROGRAM.\n\n    (a) In General.--The Secretary of Health and Human Services \n(referred to in this section as the ``Secretary'') shall carry out \nthrough the National Institutes of Health a program to be known as the \n``Pain Therapy Screening Program'' that focuses on the development of \npain therapeutics.\n    (b) Grants.--The Secretary shall award grants under the program \nunder subsection (a) to eligible public and private nonprofit entities \nto support the development of new pre-clinical models for pain \ndisorders, and the application of these models in drug, device, or \nother therapy screening.\n    (c) Model.--The program under this section shall be modeled after \nthe Epilepsy Therapy Screening Program carried out by the National \nInstitute of Neurological Disorders and Stroke.\n    (d) Fees.--The Secretary of Health and Human Services may assess \nreasonable fees on private pharmaceutical or medical device industry \nentities that utilize the program under this section to screen \nproprietary molecular compounds and devices. Such fees shall be paid to \nthe Foundation for the National Institutes of Health and transferred to \nthe NIH Innovation Account to be used for the Opioids and STOP Pain \nInitiative established under section 2.\n    (e) Funding.--The Director of the National Institutes of Health \nshall determine the amount, and allocate, funds from the amount \nappropriated under section 3, to carry out this section.\n\nSEC. 5. FUNDING PROVISIONS.\n\n    (a) Supplement Not Supplant.--Amounts appropriated in this Act \n(including the amendments made by this Act) shall be used to \nsupplement, not supplant, current funding for pain and opioid research \nat the National Institutes of Health.\n    (b) Acceptance of Donations.--Notwithstanding section 1342 of title \n31, United States Code, the Secretary of Health and Human Services may \naccept donations (including from the pharmaceutical and medical device \nindustries) to be used to assist in carrying out programs and \nactivities under this Act (and the amendments made by this Act). Such \ndonations shall be paid to the Foundation for the National Institutes \nof Health and transferred to the NIH Innovation Account to be used for \nthe Opioids and STOP Pain Initiative established under section 2.\n    (c) Inclusion of Contribution Amounts in Basic Research for \nPurposes of Research Credit.--\n            (1) In general.--Paragraph (6) of section 41(e) of the \n        Internal Revenue Code of 1986 is amended by adding at the end \n        the following new subparagraph:\n                    ``(E) Opioids and stop pain initiative.--The \n                National Institutes of Health, if the payment is made \n                in support of the Opioids and STOP Pain Initiative, as \n                established by the Opioids and STOP Pain Initiative \n                Act.''.\n            (2) Effective date.--The amendments made by this subsection \n        shall apply to taxable years beginning after the date of the \n        enactment of this Act.\n\nSEC. 6. AUTHORITY.\n\n    Notwithstanding any other provision of the law, the Director of the \nNational Institutes of Health may use funds available under section 3 \nto enter into transactions (other than contracts, cooperative \nagreements, or grants) to carry out research identified pursuant to the \nOpioids and STOP Pain Initiative established under section 2.\n\nSEC. 7. REPORTS.\n\n    (a) Annual Reports.--Not later than October 1 of each of fiscal \nyears 2019 through 2026, the Director of the National Institutes of \nHealth shall submit to the Committee on Health, Education, Labor, and \nPensions and the Committee on Appropriations of the Senate and the \nCommittee on Energy and Commerce and the Committee on Appropriations of \nthe House of Representatives, a report that includes--\n            (1) the amount obligated or expended in the fiscal year \n        prior to the fiscal year in which the report is being submitted \n        for each program or activity described in this Act (or an \n        amendment made by this Act);\n            (2) a description of all such programs or activities \n        carried out using funds provided under this Act (or \n        amendments); and\n            (3) a description of how such programs or activities are \n        advancing public health, including the impact on treating pain \n        and addressing opioid misuse in the United States.\n    (b) Additional Reports.--At the request of the Committee on Health, \nEducation, Labor, and Pensions or the Committee on Appropriations of \nthe Senate, or the Committee on Energy and Commerce or the Committee on \nAppropriations of the House of Representatives, the Director of the \nNational Institutes of Health shall provide to the relevant Committee \nan update in the form of testimony and additional reports concerning \nthe allocation of funding under this Act (or the amendments made by \nthis Act) or the description of the programs and activities carried out \nwith such funding."
}